Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 2Sarcoma, Myeloid 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Biphenotypic, Acute 1Down Syndrome 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 66Rituximab 43fludarabine phosphate 37Methotrexate 36Whole-Body Irradiation 34Peripheral Blood Stem Cell Transplantation 34Vincristine 33Etoposide 32Cytarabine 29Mycophenolic Acid 28Tacrolimus 23Busulfan 23Prednisone 22Doxorubicin 22Filgrastim 21merphos 20Dexamethasone 20Cyclosporine 19Melphalan 18Calcium Dobesilate 18Granulocyte Colony-Stimulating Factor 17Antilymphocyte Serum 17Radiotherapy 16Leucovorin 15dexamethasone acetate 14dexamethasone 21-phosphate 14auricularum 13prednylidene 12deltacortene 12azathiopurine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Burkitt Lymphoma × Leyk × Clear all
NCT02101853 2026-06-03

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
669 enrolled 14 charts
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡